-
黏膜相关淋巴组织(mucosa-associated lymphoid tissue,MALT)淋巴瘤是结外淋巴瘤的一种少见类型。肺MALT淋巴瘤是最常见的原发性肺淋巴瘤,发病年龄约为60岁,偶发于年轻患者[1]。其恶性程度低、进展缓慢、影像表现缺乏特异性、误诊率较高。目前,肺癌是引起全球男性及女性癌症相关死亡的首要原因,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占原发性肺癌的85%[2]。PET/CT能同时提供解剖及代谢信息,在肿瘤的诊断、分期、疗效评价、预后预测等方面有广泛的应用。美国国立综合癌症网络(national comprehensive cancer network,NCCN)指南推荐将PET/CT作为NSCLC的初始评估及诱导治疗后的再分期评估的常用方法[3]。目前,关于PET/CT对肺癌和肺部炎性结节鉴别诊断的相关研究较多,但关于炎症型NSCLC与肺MALT淋巴瘤的鉴别诊断研究较少,在临床工作中,二者的鉴别有一定难度。本研究通过对比炎症型NSCLC与肺MALT淋巴瘤的PET/CT影像表现,旨在提高对这2种疾病诊断的准确性。
-
由表1可知,21例肺MALT淋巴瘤患者中,肿块型少于实变型,33例炎症型NSCLC患者中,肿块型稍多于实变型,二者的差异有统计学意义(P=0.037);肺MALT淋巴瘤患者中空气支气管征的比例高于炎症型NSCLC,但差异无统计学意义(P=0.318);肺MALT淋巴瘤合并高代谢淋巴结的比例明显低于炎症型NSCLC,但差异无统计学意义(P=0.070);肺MALT淋巴瘤患者单侧发病的比例低于双侧发病,炎症型NSCLC患者单侧发病的比例高于双侧发病,二者的差异有统计学意义(P<0.001);肺MALT淋巴瘤患者中脾脏高代谢者11例,炎症型NSCLC患者中均未见脾脏高代谢者,二者差异有统计学意义(P<0.001)。肺MALT淋巴瘤与炎症型NSCLC典型病例的PET/CT显像对比见图1。
患者类型 病变形态 空气支气管征 合并高代谢淋巴结 病变位置 脾脏高代谢 肿块型 实变型 单侧 双侧 肺MALT淋巴瘤(n=21) 6(28.6) 15(71.4) 19(90.5) 3(14.3) 5(23.8) 18(85.7) 11(52.4) 炎症型NSCLC(n=33) 19(57.6) 14(42.4) 25(75.8) 16(48.5) 28(84.8) 5(15.2) 0 χ2值 4.342 0.996 3.288 26.133 21.708 P值 0.037 0.318 0.070 <0.001 <0.001 注:MALT为黏膜相关淋巴组织;NSCLC为非小细胞肺癌 表 1 肺MALT淋巴瘤与炎症型NSCLC患者的影像征象比较 [例(%)]
Table 1. Comparison of imaging signs between pulmonary mucosa-associated lymphoid tissue lymphoma patients and inflammatory-type non-small cell lung cancer patients (case (%))
-
由表2可知,肺MALT淋巴瘤患者的肿瘤长径及短径均较炎症型NSCLC患者短,但差异无统计学意义(均P>0.05);肺MALT淋巴瘤患者的CT值较炎症型NSCLC患者高,SUVmax和SUVpeak均较炎症型NSCLC患者低,且差异均有统计学意义(均P<0.01)。
患者类型 病变长径(cm) 病变短径(cm) CT值(HU) SUVmax SUVpeak 肺MALT淋巴瘤(n=21) 5.89±2.14 3.88±1.98 45.4±10.5 5.71±2.10 4.48±2.31 炎症型NSCLC(n=33) 6.26±2.75 4.21±1.56 21.6±50.1 9.89±4.53 7.46±4.44 t值 −1.46 −1.87 30.89 −4.58 −3.23 P值 0.156 0.064 <0.001 <0.001 0.002 注:MALT为黏膜相关淋巴组织;NSCLC为非小细胞肺癌;PET为正电子发射断层显像术;CT为计算机体层摄影术; SUVmax为最大标准化摄取值;SUVpeak为峰值标准化摄取值 表 2 肺MALT淋巴瘤与炎症型NSCLC患者病变的PET/CT参数比较(
)$\bar x \pm s $ Table 2. Comparison of PET/CT parameters of lesions between pulmonary mucosa-associated lymphoid tissue lymphoma patients and inflammatory-type non-small cell lung cancer patients (
)$\bar x \pm s $
18F-FDG PET/CT在肺黏膜相关淋巴组织淋巴瘤与炎症型非小细胞肺癌鉴别诊断中的价值
Differential diagnostic value of 18F-FDG PET/CT between pulmonary mucosa-associated lymphoid tissue lymphoma and inflammatory-type non-small cell lung cancer
-
摘要:
目的 探讨18F-氟脱氧葡萄糖(FDG) PET/CT的影像特征在肺黏膜相关淋巴组织(MALT)淋巴瘤及炎症型非小细胞肺癌(NSCLC)中的鉴别诊断价值。 方法 回顾性分析2015年1月至2020年12月于福建医科大学附属协和医院行18F-FDG PET/CT、肺部表现为类炎症改变并经组织病理学检查确诊的21例肺MALT淋巴瘤患者[男性13例、女性8例,年龄56~74(66.2±5.8)岁]及33例炎症型NSCLC患者[男性20例、女性13例,年龄48~84(64.6±9.6)岁]的临床资料。手动勾画CT及PET的感兴趣区,测量病变最大截面的长径及短径、CT值、最大标准化摄取值(SUVmax)和峰值标准化摄取值(SUVpeak),分析影像征象(病变形态、支气管征、病变位置、淋巴结及脾脏的代谢情况)。采用χ2检验、独立样本t检验及校正t检验比较2组间的差异。 结果 21例肺MALT淋巴瘤患者中,肿块型少于实变型(28.6%对71.4%),33例炎症型NSCLC患者中,肿块型多于实变型(57.6%对42.4%),二者的差异有统计学意义(χ2=4.342,P=0.037);肺MALT淋巴瘤患者中空气支气管征的比例高于炎症型NSCLC患者(90.5%对75.8%),合并高代谢淋巴结的比例明显低于炎症型NSCLC(14.3%对48.5%),二者的差异均无统计学意义( χ2= 0.996、3.288,均 P>0.05);肺MALT淋巴瘤患者中单侧发病的比例低于双侧发病(23.8%对85.7%),炎症型NSCLC患者中,单侧发病的比例高于双侧发病(84.8%对15.2%),二者的差异有统计学意义(χ2=26.133,P<0.001);肺MALT淋巴瘤患者中脾脏高代谢者11例(52.4%),炎症型NSCLC患者中未见脾脏高代谢者,二者的差异有统计学意义(χ2=21.708,P<0.001)。肺MALT淋巴瘤患者的长径和短径较炎症型NSCLC患者短 [(5.89±2.14) cm对(6.26±2.75) cm、(3.88±1.98) cm对(4.21±1.56) cm],二者的差异均无统计学意义(t=−1.46、−1.87,均P>0.05)。肺MALT淋巴瘤患者的CT值高于炎症型NSCLC患者[(45.4±10.5) HU对(21.6±50.1) HU],且差异有统计学意义(t=30.89,P<0.001);肺MALT淋巴瘤患者的SUVmax和SUVpeak较炎症型NSCLC患者低[(5.71±2.10)对(9.89±4.53)、(4.48±2.31)对(7.46±4.44)],且差异均有统计学意义(t=−4.58、−3.23,均P<0.01)。 结论 18F-FDG PET/CT对于肺MALT淋巴瘤和炎症型NSCLC的鉴别诊断具有重要的价值,其中SUVmax、SUVpeak、脾脏代谢情况以及CT图像中的病变形态、病变位置、CT值等可作为参考指标。 -
关键词:
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 癌,非小细胞肺 /
- 淋巴瘤,B细胞,边缘区 /
- 肺肿瘤
Abstract:Objective To investigate the imaging features of 18F-fluorodeoxyglucose (FDG) PET/CT in pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma and differential diagnosis value in inflammatory-type non-small cell lung cancer (NSCLC). Methods Retrospectively analyzed the clinical data of 21 patients with pulmonary MALT lymphoma (13 males and 8 females, aged 56~74(66.2±5.8) and 33 patients with inflammatory-type NSCLC (20 males and 13 females, aged 48~84(64.6±9.6)), respectively, who underwent 18F-FDG PET/CT from January 2015 to December 2020 at Fujian Medical University Union Hospital. In addition, the included patients were those whose lungs showed inflammation-like changes and were confirmed by histopathological examination. The CT and PET regions of interest were manually outlined. Then, the long and short diameters of the largest cross-sections of the lesions, CT values, maximum standardized uptake values (SUVmax), and peak standardized uptake values (SUVpeak) were measured. Moreover, the imaging signs (lesion morphology, bronchial signs, location of lesion onset, lymph node and spleen metabolism) were analyzed. The differences between the two groups were subsequently compared using the χ2 test, independent samples t-test, and corrected t-test. Results There were fewer masses than solids in 21 patients with pulmonary MALT lymphoma (28.6% vs.71.4%) and more masses than solids in 33 patients with inflammatory-type NSCLC (57.6% vs. 42.4%), with a statistically significant difference between the two groups (χ2=4.342, P=0.037); the proportion of bronchial signs was higher in patients with pulmonary MALT lymphoma than that in patients with inflammatory-type NSCLC (90.5% vs. 75.8%), and the proportion of combined hypermetabolic lymph nodes was significantly lower than that in inflammatory-type NSCLC (14.3% vs. 48.5%), with no statistically significant difference between the two group (χ2=0.996, 3.288; both P>0.05); there were fewer unilateral than bilateral morbidities in patients with pulmonary MALT lymphoma (23.8% vs. 85.7%) and more unilateral than bilateral in patients with inflammatory-type NSCLC (84.8% vs.15.2%), with a statistically significant difference between the two groups (χ2=26.133, P<0.001); 11 cases of splenic hypermetabolism in patients with pulmonary MALT lymphoma (52.4%) and none in inflammatory-type NSCLC, with a statistically significant difference between the two groups (χ2=21.708, P<0.001). The mean long and short diameters of patients with pulmonary MALT lymphoma were shorter than those of patients with inflammatory-type NSCLC [(5.89±2.14) cm vs. (6.26±2.75) cm, (3.88±1.98) cm vs. (4.21±1.56) cm], with no statistically significant difference between the two groups (t=−1.46, −1.87; both P>0.05). CT values were higher in patients with pulmonary MALT lymphoma than that in patients with inflammatory-type NSCLC [(45.4±10.5) HU vs.(21.6±50.1) HU], and the difference between them was statistically significant (t=30.89, P<0.001); SUVmax and SUVpeak were lower in patients with pulmonary MALT lymphoma than those in patients with inflammatory-type NSCLC [(5.71±2.10) vs. (9.89±4.53), (4.48±2.31) vs. (7.46±4.44)], and the differences between them were statistically significant (t=−4.58, −3.23; both P<0.01). Conclusions 18F-FDG PET/CT is of great value for the differential diagnosis of pulmonary MALT lymphoma and inflammatory-type NSCLC, in which SUVmax, SUVpeak, spleen metabolism, lesion morphology, lesion onset, and CT value in CT images can be used as reference indicators. -
表 1 肺MALT淋巴瘤与炎症型NSCLC患者的影像征象比较 [例(%)]
Table 1. Comparison of imaging signs between pulmonary mucosa-associated lymphoid tissue lymphoma patients and inflammatory-type non-small cell lung cancer patients (case (%))
患者类型 病变形态 空气支气管征 合并高代谢淋巴结 病变位置 脾脏高代谢 肿块型 实变型 单侧 双侧 肺MALT淋巴瘤(n=21) 6(28.6) 15(71.4) 19(90.5) 3(14.3) 5(23.8) 18(85.7) 11(52.4) 炎症型NSCLC(n=33) 19(57.6) 14(42.4) 25(75.8) 16(48.5) 28(84.8) 5(15.2) 0 χ2值 4.342 0.996 3.288 26.133 21.708 P值 0.037 0.318 0.070 <0.001 <0.001 注:MALT为黏膜相关淋巴组织;NSCLC为非小细胞肺癌 表 2 肺MALT淋巴瘤与炎症型NSCLC患者病变的PET/CT参数比较(
)$\bar x \pm s $ Table 2. Comparison of PET/CT parameters of lesions between pulmonary mucosa-associated lymphoid tissue lymphoma patients and inflammatory-type non-small cell lung cancer patients (
)$\bar x \pm s $ 患者类型 病变长径(cm) 病变短径(cm) CT值(HU) SUVmax SUVpeak 肺MALT淋巴瘤(n=21) 5.89±2.14 3.88±1.98 45.4±10.5 5.71±2.10 4.48±2.31 炎症型NSCLC(n=33) 6.26±2.75 4.21±1.56 21.6±50.1 9.89±4.53 7.46±4.44 t值 −1.46 −1.87 30.89 −4.58 −3.23 P值 0.156 0.064 <0.001 <0.001 0.002 注:MALT为黏膜相关淋巴组织;NSCLC为非小细胞肺癌;PET为正电子发射断层显像术;CT为计算机体层摄影术; SUVmax为最大标准化摄取值;SUVpeak为峰值标准化摄取值 -
[1] Sirajuddin A, Raparia K, Lewis VA, et al. Primary pulmonary lymphoid lesions: radiologic and pathologic findings[J]. Radiographics, 2016, 36(1): 53−70. DOI: 10.1148/rg.2016140339. [2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394−424. DOI: 10.3322/caac.21492. [3] Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018[J]. J Natl Compr Canc Netw, 2018, 16(7): 807−821. DOI: 10.6004/jnccn.2018.0062. [4] Deng W, Wan Y, Yu JQ. Pulmonary MALT lymphoma has variable features on CT[J/OL]. Sci Rep, 2019, 9(1): 8657[2021-02-16]. https://www.nature.com/articles/s41598-019-45144-9. DOI: 10.1038/s41598-019-45144-9. [5] Ferraro P, Trastek VF, Adlakha H, et al. Primary non-Hodgkin's lymphoma of the lung[J]. Ann Thorac Surg, 2000, 69(4): 993−997. DOI: 10.1016/s0003-4975(99)01535-0. [6] Kawashima T, Nishimura H, Akiyama H, et al. Primary pulmonary mucosa-associated lymphoid tissue lymphoma combined with idiopathic thrombocytopenic purpura and amyloidoma in the lung[J]. J Nippon Med Sch, 2005, 72(6): 370−374. DOI: 10.1272/jnms.72.370. [7] 彭思达, 谭获, 黄振倩, 等. 肺黏膜相关淋巴组织样淋巴瘤7例并临床诊断与分析[J]. 中国肿瘤临床, 2014, 41(14): 922−924. DOI: 10.3969/j.issn.1000-8179.20131268.
Peng SD, Tan H, Huang ZQ, et al. Clinical diagnosis and analysis of primary pulmonary mucosa-associated lymphoid tissue lymphoma: a report of seven cases[J]. Chin J Clin Oncol, 2014, 41(14): 922−924. DOI: 10.3969/j.issn.1000-8179.20131268.[8] 陈勃江, 高俊, 唐源, 等. 肺粘膜相关淋巴组织边缘区B细胞淋巴瘤的临床病理分析[J]. 中国肺癌杂志, 2011, 14(5): 446−451. DOI: 10.3779/j.issn.1009-3419.2011.05.12.
Chen BJ, Gao J, Tang Y, et al. Clinicopathological analysis of pulmonary marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue[J]. Chin J Lung Cancer, 2011, 14(5): 446−451. DOI: 10.3779/j.issn.1009-3419.2011.05.12.[9] Jung JI, Kim H, Park SH, et al. CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia[J]. Br J Radiol, 2001, 74(882): 490−494. DOI: 10.1259/bjr.74.882.740490. [10] Akata S, Fukushima A, Kakizaki D, et al. CT scanning of bronchioloalveolar carcinoma: specific appearances[J]. Lung Cancer, 1995, 12(3): 221−230. DOI: 10.1016/0169-5002(95)00445-7. [11] Albano D, Borghesi A, Bosio G, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma: 18F-FDG PET/CT and CT findings in 28 patients[J]. Br J Radiol, 2017, 90(1079): 20170311. DOI: 10.1259/bjr.20170311. [12] Albano D, Durmo R, Treglia G, et al. 18F-FDG PET/CT or PET role in MALT lymphoma: an open issue not yet solved-a critical review[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(3): 137−146. DOI: 10.1016/j.clml.2019.10.006. [13] Cohen D, Perry C, Hazut-Krauthammer S, et al. Is there a role for [18F]FDG PET-CT in staging MALT lymphoma?[J/OL]. Cancers, 2022, 14(3): 750[2022-02-16]. https://www.mdpi.com/2072-6694/14/3/750. DOI: 10.3390/cancers14030750. [14] 雷强, 李新春, 万齐, 等. 肺黏膜相关淋巴组织淋巴瘤的CT、PET/CT表现及预后随访[J]. 中国临床医学影像杂志, 2018, 29(9): 620−623, 639. DOI: 10.12117/jccmi.2018.09.004.
Lei Q, Li XC, Wan Q, et al. Pulmonary mucosa-associated lymphoid tissue lymphoma: CT and PET/CT imaging findings and follow-up[J]. J China Clin Med Imag, 2018, 29(9): 620−623, 639. DOI: 10.12117/jccmi.2018.09.004.[15] Husnain M, Kuker R, Reis IM, et al. Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: a single center analysis[J/OL]. Cancer Med, 2020, 9(14): 5051−5064[2022-02-16]. https://onlinelibrary.wiley.com/doi/10.1002/cam4.3096. DOI: 10.1002/cam4.3096. [16] Hoffmann M, Wöhrer S, Becherer A, et al. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference[J]. Ann Oncol, 2006, 17(12): 1761−1765. DOI: 10.1093/annonc/mdl295. [17] Albano D, Bosio G, Giubbini R, et al. 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation[J]. Leuk Lymphoma, 2017, 58(10): 2328−2334. DOI: 10.1080/10428194.2017.1298754. [18] Albano D, Bosio G, Camoni L, et al. Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma[J]. Hematol Oncol, 2019, 37(1): 39−46. DOI: 10.1002/hon.2563. [19] Zhao J, Wang HQ. Correlation between 18F-FDG PET/CT semiquantitative parameters and Ki-67 expression in pulmonary mucosa-associated lymphoid tissue lymphoma[J]. J Med Imaging Radiat Oncol, 2021, 65(2): 188−194. DOI: 10.1111/1754-9485.13146. [20] Yang XB, Min XX, He WM. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: a case report[J]. Medicine, 2018, 97(21): e10845. DOI: 10.1097/MD.0000000000010845. [21] Wainer Z, Daniels MG, Callahan J, et al. Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer[J]. J Nucl Med, 2012, 53(11): 1676−1685. DOI: 10.2967/jnumed.112.105197. [22] Mercieca S, Belderbos J, Van Loon J, et al. Comparison of SUVmax and SUVpeak based segmentation to determine primary lung tumour volume on FDG PET-CT correlated with pathology data[J]. Radiother Oncol, 2018, 129(2): 227−233. DOI: 10.1016/j.radonc.2018.06.028.